FDA Proposes Changes to Informed Consent Rules

The US Food and Drug Administration (FDA) on Tuesday proposed changes that would allow institutional review boards (IRBs) to waive or alter requirements for obtaining informed consent for certain clinical trials involving minimal risk to participants.